Drug switch study bolsters case for using copies of biotech medicine
London
NEW clinical data has bolstered the case for using cheaper copies of expensive biotech drugs by showing that patients with rheumatic diseases can be safely and effectively switched from original-brand medicine to a lower-cost version.
While the first copies of a blockbuster antibody drug for rheumatoid arthritis are now on sale in Europe, such so-called biosimilars have so far been used mainly in new patients, given doubts about how existing patients might react to a switch.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue